Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Genitourinary Cancers
•
Medical Oncology
•
Renal Cell Carcinoma
•
Urology
•
Urologic Oncology
•
Survivorship
What is your approach to surveillance in patients with no evidence of disease after treatment of oligometastatic renal cell carcinoma?
How long do you generally continue clinical and/or imaging surveillance?
Related Questions
For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?
How do you decide between internal versus external decompression of malignant obstruction of the ureter (MUO)?
For patients with oligo-progressive prostate cancer fit for metastasis-directed therapy but ineligible for radiotherapy or surgery, how do you decide between the types of ablation available?
Is there evidence that prostatectomy improves overall survival in local recurrence of prostate cancer post-definitive radiation?
How often do you monitor for pancreatitis (check lipase/amylase) while on Axitinib?
Do you recommend any alternative schedule for Cabozantinib to make treatment compliance easier for patients with metastatic renal cell carcinoma?
How do you manage hypoxia induced by belzutifan?
How would you approach a patient with metastatic renal cell carcinoma who developed a STEMI while on TKI (Lenvatinib) and immunotherapy combination?
What are your top takeaways in GU Cancers from ESMO 2024?
Why is there a benefit of ADT for high risk prostate cancer treated with radiation, yet no large trials describing benefit of adjuvant ADT after radical prostatectomy?